News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
72,665 Results
Type
Article (2319)
Company Profile (12)
Press Release (70334)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (32808)
Career Advice (40)
Deals (5132)
Drug Delivery (6)
Drug Development (7938)
Employer Resources (6)
FDA (1396)
Job Trends (1743)
News (45127)
Policy (2309)
Tag
Academia (146)
Accelerated approval (3)
Allergies (16)
Alliances (3354)
ALS (13)
Alzheimer's disease (123)
Antibody-drug conjugate (ADC) (42)
Approvals (1475)
Artificial intelligence (23)
Autoimmune disease (10)
Automation (4)
Bankruptcy (25)
Best Places to Work (1676)
Biosimilars (12)
Biotechnology (11)
Bladder cancer (25)
Brain cancer (3)
Breast cancer (103)
Cancer (642)
Cardiovascular disease (52)
Career advice (39)
Career pathing (1)
CAR-T (13)
CDC (4)
Cell therapy (54)
Cervical cancer (5)
Clinical research (7490)
Collaboration (122)
Company closure (1)
Compensation (65)
Complete response letters (2)
COVID-19 (186)
CRISPR (6)
C-suite (51)
Cystic fibrosis (11)
Data (880)
Depression (12)
Diabetes (46)
Diagnostics (987)
Digital health (6)
Diversity (1)
Diversity, equity & inclusion (1)
Drug discovery (14)
Drug pricing (11)
Duchenne muscular dystrophy (26)
Earnings (29637)
Editorial (1)
Employer branding (2)
Employer resources (6)
Events (7024)
Executive appointments (34)
FDA (1929)
Fibrodysplasia Ossificans Progressiva (2)
Frontotemporal dementia (7)
Funding (107)
Gene editing (12)
Gene therapy (36)
GLP-1 (125)
Government (258)
Grass and pollen (1)
Guidances (282)
Healthcare (2152)
HIV (7)
Huntington's disease (8)
IgA nephropathy (13)
Immunology and inflammation (25)
Immuno-oncology (9)
Indications (15)
Infectious disease (218)
Inflammatory bowel disease (9)
Influenza (12)
Intellectual property (16)
Interviews (3)
IPO (3792)
IRA (4)
Job creations (151)
Job search strategy (33)
JPM (2)
Kidney cancer (2)
Labor market (14)
Layoffs (33)
Leadership (1)
Legal (345)
Liver cancer (7)
Lung cancer (118)
Lymphoma (78)
Machine learning (2)
Management (2)
Manufacturing (62)
MASH (53)
Medical device (1864)
Medtech (1873)
Mergers & acquisitions (1470)
Metabolic disorders (173)
Multiple sclerosis (41)
NASH (5)
Neurodegenerative disease (22)
Neuropsychiatric disorders (11)
Neuroscience (259)
NextGen: Class of 2026 (397)
Non-profit (200)
Now hiring (5)
Obesity (66)
Opinion (5)
Ovarian cancer (9)
Pain (17)
Pancreatic cancer (23)
Parkinson's disease (18)
Partnered (4)
Patents (41)
Patient recruitment (35)
Peanut (7)
People (2385)
Pharmaceutical (5)
Pharmacy benefit managers (3)
Phase 1 (1694)
Phase 2 (3016)
Phase 3 (3256)
Pipeline (1502)
Policy (11)
Postmarket research (293)
Preclinical (550)
Prostate cancer (28)
Psychedelics (2)
Radiopharmaceuticals (41)
Rare diseases (59)
Real estate (313)
Recruiting (2)
Regulatory (2104)
Reports (13)
Research institute (183)
Resumes & cover letters (3)
Rett syndrome (3)
RSV (11)
Schizophrenia (22)
Series A (13)
Series B (10)
Sickle cell disease (7)
Special edition (4)
Spinal muscular atrophy (6)
Sponsored (2)
Startups (153)
Stomach cancer (3)
Supply chain (6)
Tariffs (4)
The Weekly (4)
Vaccines (92)
Venture capital (7)
Weight loss (49)
Women's health (10)
Worklife (1)
Date
Today (11)
Last 7 days (66)
Last 30 days (193)
Last 365 days (4442)
2026 (270)
2025 (4528)
2024 (5183)
2023 (5797)
2022 (6576)
2021 (7636)
2020 (6259)
2019 (4982)
2018 (3644)
2017 (3449)
2016 (2471)
2015 (3228)
2014 (2242)
2013 (1695)
2012 (2072)
2011 (2074)
2010 (1683)
Location
Africa (40)
Alabama (8)
Arizona (23)
Asia (3934)
Australia (570)
California (1334)
Canada (452)
China (90)
Colorado (63)
Connecticut (76)
Delaware (78)
Europe (16333)
Florida (178)
Georgia (58)
Idaho (7)
Illinois (93)
India (5)
Indiana (91)
Iowa (2)
Japan (65)
Kansas (12)
Kentucky (3)
Louisiana (9)
Maine (13)
Maryland (167)
Massachusetts (1072)
Michigan (45)
Minnesota (116)
Missouri (13)
Montana (4)
Nebraska (3)
Nevada (14)
New Hampshire (12)
New Jersey (483)
New York (503)
North Carolina (208)
Northern California (707)
Ohio (30)
Oregon (1)
Pennsylvania (289)
Puerto Rico (1)
Rhode Island (2)
South America (107)
South Carolina (3)
South Dakota (1)
Southern California (520)
Tennessee (13)
Texas (222)
United States (5276)
Utah (46)
Virginia (19)
Washington D.C. (6)
Washington State (98)
Wisconsin (13)
72,665 Results for "49".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 49th Annual Midwinter Meeting
February 6, 2026
·
3 min read
Mergers & acquisitions
Pfizer Stages Obesity Comeback With $4.9B Metsera Acquisition
The acquisition of breakout obesity star Metsera should pump new life into Pfizer’s portfolio, which over the last two years has suffered from three discontinued assets.
September 22, 2025
·
2 min read
·
Tristan Manalac
Neuropsychiatric disorders
Alector Scraps Dementia Drug After Phase III Flop, Lays Off 49% of Staff
This represents Alector’s second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in Alzheimer’s last November. On latozinemab for frontotemporal dementia, Alector was working with GSK, which fronted $700 million in 2021 to collaborate on two programs.
October 22, 2025
·
2 min read
·
Tristan Manalac
Obesity
Metsera’s Obesity Drug Shows ‘Very Encouraging’ Mid-Stage Efficacy, Supporting Pfizer’s $4.9B Bet
MET-097i’s mid-stage performance “bodes well” for Pfizer’s proposed buyout of Metsera, according to BMO Capital Markets, a deal centered heavily on the investigational GLP-1 drug.
September 30, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Immuron - FY25 global sales exceed projection, up 49% on prior year
July 17, 2025
·
4 min read
Press Releases
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
July 15, 2025
·
12 min read
Press Releases
Statens Serum Institut Large Danish Study Finds No Link Between Vaccines and Autism or 49 Other Health Conditions
July 16, 2025
·
2 min read
Press Releases
Lighthouse Pharmaceuticals Receives $49.2 Million Grant from NIA to Advance Phase 2 Study of LHP588 for P. gingivalis-positive Alzheimer’s Disease
August 22, 2025
·
3 min read
Press Releases
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20
November 7, 2025
·
9 min read
Press Releases
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
October 7, 2025
·
13 min read
1 of 7,267
Next
